Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 141

1.

Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome.

Venner CP, Woltosz JW, Nevill TJ, Deeg HJ, Caceres G, Platzbecker U, Scott BL, Sokol L, Sung S, List AF, Karsan A.

Haematologica. 2013 Mar;98(3):409-13. doi: 10.3324/haematol.2012.066068. Epub 2012 Aug 28.

PMID:
22929976
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Persistent malignant stem cells in del(5q) myelodysplasia in remission.

Tehranchi R, Woll PS, Anderson K, Buza-Vidas N, Mizukami T, Mead AJ, Astrand-Grundström I, Strömbeck B, Horvat A, Ferry H, Dhanda RS, Hast R, Rydén T, Vyas P, Göhring G, Schlegelberger B, Johansson B, Hellström-Lindberg E, List A, Nilsson L, Jacobsen SE.

N Engl J Med. 2010 Sep 9;363(11):1025-37. doi: 10.1056/NEJMoa0912228.

PMID:
20825315
[PubMed - indexed for MEDLINE]
Free Article
3.

Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.

Ximeri M, Galanopoulos A, Klaus M, Parcharidou A, Giannikou K, Psyllaki M, Symeonidis A, Pappa V, Kartasis Z, Liapi D, Hatzimichael E, Kokoris S, Korkolopoulou P, Sambani C, Pontikoglou C, Papadaki HA; Hellenic MDS Study Group.

Haematologica. 2010 Mar;95(3):406-14. doi: 10.3324/haematol.2009.010876. Epub 2009 Sep 22.

PMID:
19773257
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells.

Mohr B, Oelschlaegel U, Thiede C, Stewart MM, Ehninger G, Platzbecker U.

Haematologica. 2009 Mar;94(3):430-1. doi: 10.3324/haematol.13865. Epub 2009 Jan 30. No abstract available.

PMID:
19181778
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.

Pellagatti A, Jädersten M, Forsblom AM, Cattan H, Christensson B, Emanuelsson EK, Merup M, Nilsson L, Samuelsson J, Sander B, Wainscoat JS, Boultwood J, Hellström-Lindberg E.

Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11406-11. Epub 2007 Jun 18.

PMID:
17576924
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.

Gaballa MR, Besa EC.

Ann Hematol. 2014 May;93(5):723-33. doi: 10.1007/s00277-014-2022-3. Epub 2014 Mar 14. Review.

PMID:
24627193
[PubMed - indexed for MEDLINE]
7.

Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.

Oliva EN, Cuzzola M, Nobile F, Ronco F, D'Errigo MG, Laganà C, Morabito F, Galimberti S, Cortelezzi A, Aloe Spiriti MA, Specchia G, Poloni A, Breccia M, Ghio R, Finelli C, Iacopino P, Alimena G, Latagliata R.

Eur J Haematol. 2010 Sep;85(3):231-5. doi: 10.1111/j.1600-0609.2010.01473.x. Epub 2010 May 17.

PMID:
20491881
[PubMed - indexed for MEDLINE]
8.

Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.

Giagounidis AA.

Semin Hematol. 2012 Oct;49(4):312-22. doi: 10.1053/j.seminhematol.2012.07.001. Review.

PMID:
23079061
[PubMed - indexed for MEDLINE]
9.

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.

Göhring G, Giagounidis A, Büsche G, Kreipe HH, Zimmermann M, Hellström-Lindberg E, Aul C, Schlegelberger B.

Ann Hematol. 2010 Apr;89(4):365-74. doi: 10.1007/s00277-009-0846-z. Epub 2009 Oct 24.

PMID:
19855965
[PubMed - indexed for MEDLINE]
10.

Differential expression of microRNAs in CD34+ cells of 5q- syndrome.

Votavova H, Grmanova M, Dostalova Merkerova M, Belickova M, Vasikova A, Neuwirtova R, Cermak J.

J Hematol Oncol. 2011 Jan 6;4:1. doi: 10.1186/1756-8722-4-1.

PMID:
21211043
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.

Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, Byrd J, Sokol L, Lawrence N, Pireddu R, Dewald G, Williams A, Maciejewski J, List A.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12974-9. doi: 10.1073/pnas.0811267106. Epub 2009 May 26. Erratum in: Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14504.

PMID:
19470455
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.

Giagounidis A, Mufti GJ, Fenaux P, Germing U, List A, MacBeth KJ.

Ann Hematol. 2014 Jan;93(1):1-11. doi: 10.1007/s00277-013-1863-5. Epub 2013 Sep 10. Review.

PMID:
24018623
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.

Heise C, Carter T, Schafer P, Chopra R.

Expert Rev Anticancer Ther. 2010 Oct;10(10):1663-72. doi: 10.1586/era.10.135. Review.

PMID:
20942636
[PubMed - indexed for MEDLINE]
14.

Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.

List AF, Baker AF, Green S, Bellamy W.

Cancer Control. 2006 Dec;13 Suppl:4-11. Review.

PMID:
17242661
[PubMed - indexed for MEDLINE]
Free Article
15.

The role of lenalidomide in the management of myelodysplasia with del 5q.

Kelaidi C, Eclache V, Fenaux P.

Br J Haematol. 2008 Feb;140(3):267-78. doi: 10.1111/j.1365-2141.2007.06910.x. Review.

PMID:
18217896
[PubMed - indexed for MEDLINE]
16.

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.

Möllgård L, Saft L, Treppendahl MB, Dybedal I, Nørgaard JM, Astermark J, Ejerblad E, Garelius H, Dufva IH, Jansson M, Jädersten M, Kjeldsen L, Linder O, Nilsson L, Vestergaard H, Porwit A, Grønbæk K, Hellström-Lindberg E.

Haematologica. 2011 Jul;96(7):963-71. doi: 10.3324/haematol.2010.039669. Erratum in: Haematologica. 2011 Aug;96(8):1240. Lindberg, Eva Hellström [corrected to Hellström-Lindberg, Eva].

PMID:
21719884
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.

Matsuda A, Taniwaki M, Jinnai I, Harada H, Watanabe M, Suzuki K, Yanagita S, Suzuki T, Yoshida Y, Kimura A, Tsudo M, Tohyama K, Takatoku M, Ozawa K.

Leuk Res. 2012 May;36(5):575-80. doi: 10.1016/j.leukres.2011.11.011. Epub 2011 Dec 15.

PMID:
22172461
[PubMed - indexed for MEDLINE]
18.

Lenalidomide for treatment of myelodysplastic syndromes.

Komrokji RS, List AF.

Curr Pharm Des. 2012;18(22):3198-203. Review.

PMID:
22571699
[PubMed - indexed for MEDLINE]
19.

Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients.

Wu L, Li X, Xu F, Zhang Z, Chang C, He Q.

Eur J Haematol. 2013 Jun;90(6):486-93. doi: 10.1111/ejh.12105. Epub 2013 Apr 23.

PMID:
23506134
[PubMed - indexed for MEDLINE]
20.

Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.

Komrokji RS, List AF.

Hematol Oncol Clin North Am. 2010 Apr;24(2):377-88. doi: 10.1016/j.hoc.2010.02.013. Review.

PMID:
20359632
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk